
Abpro Stock
Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.
Sign up today and learn more about Abpro Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Abpro Stock
Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.
Funding History
March 2016 | $12.4M |
---|---|
April 2017 | $10.0M |
January 2020 | $18.0M |
April 2022 | $2.0M |
Management
CEO & CO-FOUNDER
Eugene Cha
SVP OF STRATEGIC ALLIANCES
John Xu
Chairman & CEO
Ian Chan
CMO & SVP
Robert J. Markelewicz
Press
bizjournals - Sep, 25 2023
Antibody maker Abpro to go public via SPAC dealfiercebiotech - Sep, 23 2023
Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPObioworld - Sep, 22 2023
Abpro gives it another go, this time with a SPACseekingalpha - Sep, 22 2023
Biotechnology company Abpro to merge with SPAC Atlantic Coastal Acquisitionbusinesswire - Sep, 21 2023
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. IIbiospace - Sep, 22 2022
Celltrion/Abpro, Merck/Nerviano and more Unite against Cancerbizjournals - Dec, 26 2021
Abpro CEO Ian Chan wants antibodies 'future-proofed' against variantsfiercebiotech - Mar, 1 2019
Bispecifics player Abpro teams up with China’s NJCTTQ in biobucks deal worth up to $4Bfiercebiotech - May, 12 2018
Bispecific antibody builder Abpro postpones $69M IPOfiercebiotech - Apr, 12 2018
Abpro files $69M IPO to take bispecific antibodies into the clinicEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase